Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in ...
Maze Therapeutics, Inc. is a clinical-stage biotechnology company headquartered at 171 Oyster Point Boulevard in South San Francisco, California. The company was incorporated in 2017 and was formerly known as Modulus Therapeutics before adopting the Maze Therapeutics name in September 2018. It listed its common stock on Nasdaq under the ...Maze Therapeutics, Inc. is a clinical-stage biotechnology company headquartered at 171 Oyster Point Boulevard in South San Francisco, California. The company was incorporated in 2017 and was formerly known as Modulus Therapeutics before adopting the Maze Therapeutics name in September 2018. It listed its common stock on Nasdaq under the symbol MAZE, with the supplied market information identifying an initial public offering date of January 31, 2025. Jason Coloma serves as chief executive officer; before becoming CEO, he served as the company’s chief operating officer.
Maze’s business model is based on translating human genetic discoveries into precision medicines. Its strategy is to identify genetic variants associated with protection from disease, understand the biological mechanisms behind those variants, and design small-molecule drugs that may mimic or enhance those beneficial effects. The company describes its proprietary Maze Compass platform as combining human genetics with functional genomics and disease biology to prioritize drug targets and guide development decisions. This approach is particularly relevant to diseases in which genetically defined patient subgroups may respond differently to treatment.
The reported pipeline centers on kidney and metabolic disorders. MZE829 is an oral small-molecule inhibitor of apolipoprotein L1, or APOL1, being developed for APOL1 kidney disease and described in the supplied information as being in a Phase II clinical trial. MZE782 is an oral small-molecule inhibitor described as Phase II-ready for phenylketonuria and chronic kidney disease. MZE001 is an investigational oral inhibitor of muscle-specific glycogen synthase under development for Pompe disease. Maze has also entered research and licensing relationships involving programs directed at UNC13A, ATXN2, and MZE001, including arrangements with Trace Neuroscience, Neurocrine Biosciences, and Shionogi.
As a clinical-stage drug developer, Maze’s principal expenses are expected to include research and development, clinical-trial execution, laboratory work, regulatory activities, employee compensation, and manufacturing of clinical-trial materials. A detailed product bill of materials, unit manufacturing cost, commercial cost of goods sold, and commercialization infrastructure have not been disclosed in the supplied information. The company reported 141 full-time employees, placing it in the 101-200 employee category.
The supplied trailing financial metrics indicate that Maze remains loss-making and cash-burning, as is common for a clinical-stage biotechnology company without an approved commercial product. Reported trailing net profit margin was approximately negative 612.7%, free cash flow was approximately negative $83.6 million, and return on equity was approximately negative 36.6%. At the same time, the company showed substantial liquidity, including a current ratio of approximately 17.9 and cash per share of approximately $6.54. Its future value depends heavily on clinical results, regulatory approvals, partnership execution, intellectual-property protection, financing capacity, and the ability to manufacture and commercialize successful therapies. The company has no reported dividend and should be viewed as a development-stage biotechnology investment with significant clinical, regulatory, financing, and commercialization risk.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
-100.0%
-100.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-131.1M
-351.0%
-84.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-112.7M
-250.7%
+61.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
6.6%
-51.4%
-25.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
15.50x
+58.9%
+2.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
